{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T23:09:10Z","timestamp":1763507350644,"version":"3.45.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-025-00656-2","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T10:58:40Z","timestamp":1763463520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A cost-utility analysis of Glecaprevir\/Pibrentasvir versus Sofosbuvir\/Daclatasvir and Sofosbuvir\/Velpatasvir for treatment of hepatitis C in Iran"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9456-471X","authenticated-orcid":false,"given":"Mojtaba","family":"Jafari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2483-4646","authenticated-orcid":false,"given":"Parisa","family":"Mehdizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5778-5502","authenticated-orcid":false,"given":"Khosro","family":"Keshavarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Teymourzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4123-3268","authenticated-orcid":false,"given":"Mohammad Ali","family":"Abyazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4443-6602","authenticated-orcid":false,"given":"Seyed Moayed","family":"Alavian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9569-564X","authenticated-orcid":false,"given":"Alijanpour","family":"Pouria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"7","key":"656_CR1","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nrmicro3046","volume":"11","author":"R Bartenschlager","year":"2013","unstructured":"Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013;11(7):482\u201396.","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"656_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.bpg.2012.09.012","volume":"26","author":"G Papatheodoridis","year":"2012","unstructured":"Papatheodoridis G, Hatzakis A. Public health issues of hepatitis C virus infection. Best Pract Res Clin Gastroenterol. 2012;26(4):371\u201380.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"10","key":"656_CR3","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.4254\/wjh.v7.i10.1377","volume":"7","author":"HC Li","year":"2015","unstructured":"Li HC, Lo SY. Hepatitis c virus: virology, diagnosis and treatment. World J Hepatol. 2015;7(10):1377\u201389.","journal-title":"World J Hepatol"},{"issue":"1","key":"656_CR4","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.11879","volume":"14","author":"MS Afzal","year":"2014","unstructured":"Afzal MS, Anjum S, Zaidi NU. Changing of HCV clade pattern in Iran; the possible means for something good. Hepat Mon. 2014;14(1):e11879.","journal-title":"Hepat Mon"},{"issue":"1","key":"656_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrgastro.2013.179","volume":"11","author":"M Thursz","year":"2014","unstructured":"Thursz M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol. 2014;11(1):28\u201335.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"656_CR6","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.cgh.2016.09.015","volume":"15","author":"J Chhatwal","year":"2017","unstructured":"Chhatwal J, He T, Hur C, Lopez-Olivo MA. Direct-Acting antiviral agents for patients with hepatitis C virus genotype 1 infection are Cost-Saving. Clin Gastroenterol Hepatol. 2017;15(6):827\u201337. e8.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"656_CR7","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3111\/13696998.2015.1044457","volume":"18","author":"K Westerhout","year":"2015","unstructured":"Westerhout K, Treur M, Mehnert A, Pascoe K, Ladha I, Belsey J. A cost utility analysis of Simeprevir used with peginterferon\u2009+\u2009ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National health service. J Med Econ. 2015;18(10):838\u201349.","journal-title":"J Med Econ"},{"issue":"1","key":"656_CR8","first-page":"41","volume":"6","author":"A Tamaddoni","year":"2007","unstructured":"Tamaddoni A, Mohammadzadeh I, Ziaei O. Seroprevalence of HCV antibody among patients with beta-thalassemia major in Amirkola thalassemia center, Iran. Iran J Allergy Asthma Immunol. 2007;6(1):41.","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"1","key":"656_CR9","first-page":"47","volume":"4","author":"SM Alavian","year":"2009","unstructured":"Alavian SM. Hepatitis C infection in Iran; a review article. Arch Clin Infect Dis. 2009;4(1):47\u201359.","journal-title":"Arch Clin Infect Dis"},{"issue":"3","key":"656_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jcv.2012.03.002","volume":"54","author":"HA Torres","year":"2012","unstructured":"Torres HA, Nevah MI, Barnett BJ, Mahale P, Kontoyiannis DP, Hassan MM, et al. Hepatitis c virus genotype distribution varies by underlying disease status among patients in the same geographic region: a retrospective multicenter study. J Clin Virol. 2012;54(3):218\u201322.","journal-title":"J Clin Virol"},{"issue":"Suppl 2","key":"656_CR11","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/S1386-6532(05)80032-0","volume":"34","author":"M Beltran","year":"2005","unstructured":"Beltran M, Navas MC, De la Hoz F, Mercedes Munoz M, Jaramillo S, Estrada C, et al. Hepatitis C virus Seroprevalence in multi-transfused patients in Colombia. J Clin Virol. 2005;34(Suppl 2):S33\u20138.","journal-title":"J Clin Virol"},{"issue":"1","key":"656_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41598-017-18296-9","volume":"8","author":"S Mahmud","year":"2018","unstructured":"Mahmud S, Akbarzadeh V, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Iran: systematic review and meta-analyses. Sci Rep. 2018;8(1):150.","journal-title":"Sci Rep"},{"issue":"3","key":"656_CR13","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.19082\/4014","volume":"9","author":"M Aminianfar","year":"2017","unstructured":"Aminianfar M, Khani F, Ghasemzadeh I. Evaluation of hepatitis C, hepatitis B, and HIV virus serology pandemic in thalassemia patients of Shahid Mohammadi hospital of Bandar Abbas, Iran. Electron Physician. 2017;9(3):4014\u20139.","journal-title":"Electron Physician"},{"key":"656_CR14","first-page":"1171","volume":"13","author":"M Afzali","year":"2015","unstructured":"Afzali M, Mirzaei M, Shoraka HR, Saadati H. Epidemiological survey of hepatitis C in Yazd during 2010\u20132012: a short report. J Rafsanjan Univ Med Sci. 2015;13:1171\u20138.","journal-title":"J Rafsanjan Univ Med Sci"},{"issue":"4","key":"656_CR15","first-page":"295","volume":"8","author":"M Kazemi Arababadi","year":"2009","unstructured":"Kazemi Arababadi M, Hassanshahi G, Rezaeian M, Rezazadeh Zarandi E, Vazirinejad R. Evaluation of occult hepatits B virus infection in thalassemic patients infected by HCV in Kerman Province of Iran. J Rafsanjan Univ Med Sci. 2009;8(4):295\u2013302.","journal-title":"J Rafsanjan Univ Med Sci"},{"issue":"11","key":"656_CR16","doi-asserted-by":"publisher","DOI":"10.5812\/ircmj.37094","volume":"18","author":"SM Alavian","year":"2016","unstructured":"Alavian SM, Nikfar S, Kebriaeezadeh A, Lotfi F, Sanati E, Rezaei Hemami M, et al. A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection. Iran Red Crescent Med J. 2016;18(11):e37094.","journal-title":"Iran Red Crescent Med J"},{"key":"656_CR17","doi-asserted-by":"crossref","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975\u201382.","DOI":"10.1056\/NEJMoa020047"},{"issue":"21","key":"656_CR18","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1056\/NEJMe1403619","volume":"370","author":"TJ Liang","year":"2014","unstructured":"Liang TJ, Ghany MG. Therapy of hepatitis C\u2013back to the future. N Engl J Med. 2014;370(21):2043\u20137.","journal-title":"N Engl J Med"},{"issue":"11","key":"656_CR19","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.25540","volume":"14","author":"MA Pourhoseingholi","year":"2014","unstructured":"Pourhoseingholi MA, Ashtari S, Alavian SM. Sofosbuvir vs. combination of pegylated interferon and ribavirin; how much shall pay for Iranian patients?? Hepat Mon. 2014;14(11):e25540.","journal-title":"Hepat Mon"},{"issue":"9","key":"656_CR20","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jval.2020.03.018","volume":"23","author":"OT Due","year":"2020","unstructured":"Due OT, Thakkinstian A, Thavorncharoensap M, Sobhonslidsuk A, Wu O, Phuong NK, et al. Cost-utility analysis of direct-acting antivirals for treatment of chronic hepatitis C genotype 1 and 6 in Vietnam. Value Health. 2020;23(9):1180\u201390.","journal-title":"Value Health"},{"issue":"3","key":"656_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1056\/NEJMoa1104430","volume":"366","author":"AS Lok","year":"2012","unstructured":"Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3):216\u201324.","journal-title":"N Engl J Med"},{"issue":"6","key":"656_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7326\/M14-1336","volume":"162","author":"J Chhatwal","year":"2015","unstructured":"Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162(6):397\u2013406.","journal-title":"Ann Intern Med"},{"issue":"8","key":"656_CR23","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon118646","volume":"21","author":"Z Goudarzi","year":"2021","unstructured":"Goudarzi Z, Poursamad A, Karimzadeh I, Jallaly N, Keshavarz K, Alavian SM. Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C. Hepat Mon. 2021;21(8):e118646.","journal-title":"Hepat Mon"},{"issue":"1","key":"656_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s12325-019-01166-3","volume":"37","author":"I Kawaguchi","year":"2020","unstructured":"Kawaguchi I, Chayama K, Gonzalez YS, Virabhak S, Mitchell D, Yuen C, et al. A cost-effectiveness analysis of glecaprevir\/pibrentasvir versus existing direct-acting antivirals to treat chronic hepatitis C in Japan. Adv Ther. 2020;37(1):457\u201376.","journal-title":"Adv Ther"},{"issue":"6","key":"656_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-058757","volume":"12","author":"M Tasavon Gholamhoseini","year":"2022","unstructured":"Tasavon Gholamhoseini M, Sharafi H, Hl Borba H, Alavian SM, Sabermahani A, Hajarizadeh B. Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study. BMJ Open. 2022;12(6):e058757.","journal-title":"BMJ Open"},{"issue":"6","key":"656_CR26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.5009\/gnl20321","volume":"15","author":"J Heo","year":"2021","unstructured":"Heo J, Kim YJ, Lee JW, Kim JH, Lim YS, Han KH, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Korean patients with chronic hepatitis C: a pooled analysis of five phase II\/III trials. Gut Liver. 2021;15(6):895\u2013903.","journal-title":"Gut Liver"},{"key":"656_CR27","doi-asserted-by":"crossref","unstructured":"Zuckerman E, Gutierrez JA, Dylla DE, de Ledinghen V, Muir AJ, Gschwantler M et al. Eight Weeks of Treatment With Glecaprevir\/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Na\u00efve Patients With Hepatitis C Virus Infection. Clin Gastroenterol Hepatol. 2020;18(11):2544-53.e6.","DOI":"10.1016\/j.cgh.2020.06.044"},{"key":"656_CR28","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0594-2019","volume":"53","author":"VL Ferreira","year":"2020","unstructured":"Ferreira VL, Leonart LP, Pedroso MLA, Pontarolo R. Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil. Rev Soc Bras Med Trop. 2020;53:e20190594.","journal-title":"Rev Soc Bras Med Trop"},{"issue":"5","key":"656_CR29","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/hep.27010","volume":"59","author":"S Petta","year":"2014","unstructured":"Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, Bruno R, et al. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2014;59(5):1692\u2013705.","journal-title":"Hepatology"},{"issue":"1","key":"656_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40008-018-0127-x","volume":"7","author":"A Daneshmand","year":"2018","unstructured":"Daneshmand A, Jahangard E, Abdollah-Milani M. A time preference measure of the social discount rate for Iran. J Econ Struct. 2018;7(1):29.","journal-title":"J Econ Struct"},{"issue":"9","key":"656_CR31","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.37435","volume":"16","author":"K Keshavarz","year":"2016","unstructured":"Keshavarz K, Kebriaeezadeh A, Alavian SM, Akbari Sari A, Rezaei Hemami M, Lotfi F, et al. A cost-utility and cost-effectiveness analysis of different oral antiviral medications in patients with HBeAg-negative chronic hepatitis B in Iran: an economic microsimulation decision model. Hepat Mon. 2016;16(9):e37435.","journal-title":"Hepat Mon"},{"issue":"3","key":"656_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40258-020-00623-3","volume":"19","author":"P Chen","year":"2021","unstructured":"Chen P, Jin M, Cao Y, Li H. Cost-effectiveness analysis of oral direct-acting antivirals for Chinese patients with chronic hepatitis C. Appl Health Econ Health Policy. 2021;19(3):371\u201387.","journal-title":"Appl Health Econ Health Policy"},{"issue":"10","key":"656_CR33","doi-asserted-by":"publisher","first-page":"10313","DOI":"10.21037\/apm-21-863","volume":"10","author":"HJ Zhou","year":"2021","unstructured":"Zhou HJ, Wu G, Li JM, Naidoo N, Xie YX, Feng BL, et al. Cost-effectiveness analysis of glecaprevir\/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection. Ann Palliat Med. 2021;10(10):10313\u201326.","journal-title":"Ann Palliat Med"},{"issue":"8","key":"656_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237582","volume":"15","author":"HH Yen","year":"2020","unstructured":"Yen HH, Su PY, Zeng YH, Liu IL, Huang SP, Hsu YC, et al. Glecaprevir-pibrentasvir for chronic hepatitis C: comparing treatment effect in patients with and without end-stage renal disease in a real-world setting. PLoS ONE. 2020;15(8):e0237582.","journal-title":"PLoS ONE"},{"issue":"2","key":"656_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229517","volume":"15","author":"A Sirinawasatien","year":"2020","unstructured":"Sirinawasatien A, Techasirioangkun T. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: real-world efficacy in Thailand. PLoS ONE. 2020;15(2):e0229517.","journal-title":"PLoS ONE"},{"issue":"3","key":"656_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3949\/ccjm.81a.13155","volume":"81","author":"M Dugum","year":"2014","unstructured":"Dugum M, O\u2019Shea R. Hepatitis C virus: here comes all-oral treatment. Cleve Clin J Med. 2014;81(3):159\u201372.","journal-title":"Cleve Clin J Med"},{"key":"656_CR37","unstructured":"World-Bank. World Development Indicator. Available from: https:\/\/data.worldbank.org\/indicator\/PA.NUS.PPP?locations=IR"},{"key":"656_CR38","unstructured":"World-Bank. World Development Indicator. Available from: https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.PP.CD?locations=IR"},{"issue":"7","key":"656_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.2202","volume":"19","author":"J Shafrin","year":"2016","unstructured":"Shafrin J, May SG, Skornicki M, Hathway J, Macaulay R, Villeneuve J, et al. Use of net monetary benefit analysis to comprehensively understand the value of innovative treatments. Value Health. 2016;19(7):A731.","journal-title":"Value Health"},{"issue":"1","key":"656_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12874-023-01956-y","volume":"23","author":"L Everest","year":"2023","unstructured":"Everest L, Chen BE, Hay AE, Cheung MC, Chan KKW. Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian cancer trials group. BMC Med Res Methodol. 2023;23(1):179.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"656_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2165\/00019053-200321010-00003","volume":"21","author":"N Zethraeus","year":"2003","unstructured":"Zethraeus N, Johannesson M, J\u00f6nsson B, L\u00f6thgren M, Tambour M. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies. Pharmacoeconomics. 2003;21(1):39\u201348.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"656_CR42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/14737167.2019.1629291","volume":"20","author":"S Gordon","year":"2020","unstructured":"Gordon S, Lee J, Smith N, Dieterich D. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic hepatitis C in the United States. Expert Rev PharmacoEcon Outcomes Res. 2020;20(3):251\u20137.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"key":"656_CR43","unstructured":"CHEN C, AI D, LU Y. Cost-effectiveness analysis of glecaprevir\/pibrentasvir versus elbasvir\/grazoprevir in chronic hepatitis C genotype 1b treatment-naive patients without cirrhosis. China Pharm. 2020:1113\u20138."}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00656-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00656-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00656-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T23:05:54Z","timestamp":1763507154000},"score":1,"resource":{"primary":{"URL":"https:\/\/resource-allocation.biomedcentral.com\/articles\/10.1186\/s12962-025-00656-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["656"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00656-2","relation":{},"ISSN":["1478-7547"],"issn-type":[{"type":"electronic","value":"1478-7547"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research purpose and methodology, including experimental protocols, were approved by the Internal Research Ethics Committee of the Baqiatallah University of Medical Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The study did not use any data on single individuals and only macro data are used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}